Combined REDV Polypeptide and Heparin onto Titanium Surface for the Hemocompatibility and Selectively Endothelialization

Kun Zhang Jian Wang

doi:10.4172/2157-7013.1000198

Abstract

To enhance the blood compatibility and selective endothelialization of the cardiovascular implants simultaneously, in this study, the mixture of REDV polypeptide and heparin was used to modify titanium (Ti) surfaces in virtue of a polylysine layer. Blood compatibility tests revealed that the modified Ti prolonged blood coagulation time compared with Ti surface. Endothelial cells (ECs)/platelets and ECs/smooth muscle cells (SMCs) competed seeding results showed more attached ECs on the modified samples than that on Ti surfaces. Thus, in vitro evaluation indicates that the REDV polypeptide and heparin modified Ti surface kept excellent biocompatibility, which could improve the blood compatibility and selectively promotes the endothelialization simultaneously. We conceive that the cooperation of REDV polypeptide and heparin may provide a promising selection for biomaterials surface modification of vascular implants.

Highlights

Cardiovascular disease caused by atherosclerosis is a significant cause of death [1]
The broad peak around 3370 cm−1 suggests that TiOH, TiOHP, TiOHPH and TiOHPHR are rich in hydroxy (–OH) groups
Amide I and amide II appear on TiOHPH and TiOHPHR, the reason is that the overlapping carboxyl stretching vibrations (1715~1650 cm−1) on heparin belong to the broad peak around 1672 cm−1, and GREDVY polypeptide has many amide bonds [15]

Summary

Introduction

Cardiovascular disease caused by atherosclerosis is a significant cause of death [1]. Endothelialization would provide an anti-thrombogenic and anti-proliferative coating on the bloodcontacting metal stent surface forever which mimics the normal lining of blood vessels [3]. The peptide sequence Arg-Glu-Asp-Val (REDV), which is present in the III-CS domain of human plasma fibronectin, is a special adhesion receptor on the human endothelial cell. GREDVY polypeptide (Gly-Arg-Glu-Asp-Val-Tyr, shown in Figure 1) which has the REDV sequence has the selective ability [5]. As a common anticoagulant in clinical, can be coated on the stents [6,7] or combing with many drugs (such as abciximab [8]) or biomolecules (such as fibronectin [9], polyl-lysine [10]) to improve the blood compatibility

Methods

Results

Conclusion